Becton, Dickinson and Company (NYSE:BDX) Issues Earnings Results

Becton, Dickinson and Company (NYSE:BDX) released its quarterly earnings results on Thursday. The medical instruments supplier reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.92 by $0.04, Zacks reports. The business had revenue of $5.89 billion during the quarter, compared to analyst estimates of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.Becton, Dickinson and Company’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.81 EPS. Becton, Dickinson and Company updated its FY 2026 guidance to 14.750-15.050 EPS.

Becton, Dickinson and Company Stock Up 0.3%

Shares of NYSE:BDX traded up $0.49 during midday trading on Friday, hitting $177.88. 3,068,583 shares of the stock were exchanged, compared to its average volume of 2,454,233. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $251.99. The business’s fifty day simple moving average is $186.77 and its two-hundred day simple moving average is $182.42. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company has a market capitalization of $50.99 billion, a PE ratio of 31.99, a P/E/G ratio of 1.42 and a beta of 0.25.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be paid a $1.05 dividend. The ex-dividend date of this dividend is Monday, December 8th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 71.36%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the sale, the director owned 35,816 shares in the company, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,249 shares of company stock valued at $231,358 over the last ninety days. Insiders own 0.36% of the company’s stock.

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of institutional investors and hedge funds have recently modified their holdings of the business. Caxton Associates LLP purchased a new stake in Becton, Dickinson and Company during the 2nd quarter valued at about $212,000. Oxford Asset Management LLP bought a new position in Becton, Dickinson and Company during the second quarter valued at $271,000. State of Wyoming purchased a new position in shares of Becton, Dickinson and Company during the second quarter valued at approximately $352,000. Teza Capital Management LLC bought a new position in Becton, Dickinson and Company in the second quarter worth approximately $379,000. Finally, Voleon Capital Management LP acquired a new position in Becton, Dickinson and Company during the 2nd quarter valued at about $381,000. 86.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Argus boosted their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday. Morgan Stanley raised their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Wells Fargo & Company increased their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Finally, Jefferies Financial Group reduced their price objective on shares of Becton, Dickinson and Company from $257.00 to $215.00 in a research note on Friday. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus price target of $203.27.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.